Detalhe da pesquisa
1.
Peptide nucleic acid-dependent artifact can lead to false-positive triplex gene editing signals.
Proc Natl Acad Sci U S A
; 118(45)2021 11 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34732575
2.
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
Bioorg Med Chem Lett
; 25(22): 5258-64, 2015 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26459208
3.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
J Transl Med
; 11: 76, 2013 Mar 23.
Artigo
Inglês
| MEDLINE | ID: mdl-23522020
4.
Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Bioorg Med Chem Lett
; 23(11): 3149-53, 2013 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23623490
5.
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Blood
; 114(13): 2721-9, 2009 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-19633198
6.
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Cancer Lett
; 440-441: 1-10, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30312729
7.
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
J Med Chem
; 62(4): 2140-2153, 2019 02 28.
Artigo
Inglês
| MEDLINE | ID: mdl-30715878
8.
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
Bioconjug Chem
; 19(8): 1673-83, 2008 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-18637680
9.
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.
J Med Chem
; 60(10): 4458-4473, 2017 05 25.
Artigo
Inglês
| MEDLINE | ID: mdl-28445037
10.
An integrative biology approach for analysis of drug action in models of human vascular inflammation.
FASEB J
; 18(11): 1279-81, 2004 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-15208272
11.
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sci Transl Med
; 7(287): 287ra70, 2015 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-25972002
12.
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
Mol Cell Biol
; 34(13): 2517-32, 2014 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-24777602
13.
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Cancer Res
; 74(19): 5561-71, 2014 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25228655
14.
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Mol Cancer Ther
; 12(7): 1255-65, 2013 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-23598530
15.
FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.
Mol Cancer Ther
; 11(10): 2222-32, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22807577
16.
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Nat Biotechnol
; 30(2): 184-9, 2012 Jan 22.
Artigo
Inglês
| MEDLINE | ID: mdl-22267010
17.
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
Sci Transl Med
; 3(74): 74ra22, 2011 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-21411738
18.
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Mol Cancer Ther
; 8(10): 2937-46, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19808977
19.
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Cancer Res
; 69(6): 2358-64, 2009 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-19258515
20.
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Blood
; 110(2): 616-23, 2007 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17374736